TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Enhanced Resilience Training to Improve Mental Health, Stress and Performance in Resident Physicians
Brief Summary: Burnout and overwhelming stress are growing issues in medicine and are associated with mental illness, performance deficits and diminished patient care. Among surgical trainees, high dispositional mindfulness decreases these risks by 75% or more, and formal mindfulness training has been shown feasible and acceptable. In other high-stress populations formal mindfulness training has improved well-being, stress, cognition and performance, yet the ability of such training to mitigate stress and burnout across medical specialties, or to affect improvements in the cognition and performance of physicians, remains unknown. To address these gaps and thereby promote the wider adoption of contemplative practices within medical training, investigators have developed Enhanced Stress Resilience Training, a modified form of MBSR - streamlined, tailored and contextualized for physicians and trainees. Investigators propose to test Enhanced Stress Resilience Training (ESRT), versus active control and residency-as-usual, in surgical and non-surgical residents evaluated for well-being, cognition and performance changes at baseline, post-intervention and six-month follow-up.


Options:
A: Arm Label: Electronic intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Electronic intervention suggesting behavioral activity | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Electronic intervention suggesting behavioral activity; Assigned to Arm(s): Electronic intervention
B: Arm Label: Mindful Awareness Practices (MAPs); Type: EXPERIMENTAL; Interventions: Behavioral: Mindful Awareness Practices (MAPs) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mindful Awareness Practices (MAPs); Assigned to Arm(s): Mindful Awareness Practices (MAPs)
C: Arm Label: Mental Training for Residents; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Stress Resilience Training (ESRT) | Arm Label: Active Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active Control | Intervention Type: BEHAVIORAL; Name: Enhanced Stress Resilience Training (ESRT); Assigned to Arm(s): Mental Training for Residents | Intervention Type: BEHAVIORAL; Name: Active Control; Assigned to Arm(s): Active Control
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Corporate Athlete Resilience (CAR) Training Program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Corporate Athlete Resilience (CAR) Training Program; Assigned to Arm(s): Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Enhanced Resilience Training to Improve Mental Health, Stress and Performance in Resident Physicians
Brief Summary: Burnout and overwhelming stress are growing issues in medicine and are associated with mental illness, performance deficits and diminished patient care. Among surgical trainees, high dispositional mindfulness decreases these risks by 75% or more, and formal mindfulness training has been shown feasible and acceptable. In other high-stress populations formal mindfulness training has improved well-being, stress, cognition and performance, yet the ability of such training to mitigate stress and burnout across medical specialties, or to affect improvements in the cognition and performance of physicians, remains unknown. To address these gaps and thereby promote the wider adoption of contemplative practices within medical training, investigators have developed Enhanced Stress Resilience Training, a modified form of MBSR - streamlined, tailored and contextualized for physicians and trainees. Investigators propose to test Enhanced Stress Resilience Training (ESRT), versus active control and residency-as-usual, in surgical and non-surgical residents evaluated for well-being, cognition and performance changes at baseline, post-intervention and six-month follow-up.


Options:
A: Arm Label: Sudarshan Kroya Yoga (SKY); Type: EXPERIMENTAL; Interventions: Other: Sudarshan Kriya Yoga (SKY) | Arm Label: Health Enhancement Program (HEP); Type: ACTIVE_COMPARATOR; Interventions: Other: Health Enhancement Program | Intervention Type: OTHER; Name: Sudarshan Kriya Yoga (SKY); Assigned to Arm(s): Sudarshan Kroya Yoga (SKY) | Intervention Type: OTHER; Name: Health Enhancement Program; Assigned to Arm(s): Health Enhancement Program (HEP)
B: Arm Label: Mindfulness; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness | Arm Label: Interpersonal effectiveness; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: interpersonal effectiveness | Intervention Type: BEHAVIORAL; Name: Mindfulness; Assigned to Arm(s): Mindfulness | Intervention Type: BEHAVIORAL; Name: interpersonal effectiveness; Assigned to Arm(s): Interpersonal effectiveness
C: Arm Label: Mental Training for Residents; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Stress Resilience Training (ESRT) | Arm Label: Active Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active Control | Intervention Type: BEHAVIORAL; Name: Enhanced Stress Resilience Training (ESRT); Assigned to Arm(s): Mental Training for Residents | Intervention Type: BEHAVIORAL; Name: Active Control; Assigned to Arm(s): Active Control
D: Arm Label: Mobile Video Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Stress management counseling | Arm Label: Offline Counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Stress management counseling | Arm Label: Selfcare; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Stress management counseling; Assigned to Arm(s): Mobile Video Counseling, Offline Counseling

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Enhanced Resilience Training to Improve Mental Health, Stress and Performance in Resident Physicians
Brief Summary: Burnout and overwhelming stress are growing issues in medicine and are associated with mental illness, performance deficits and diminished patient care. Among surgical trainees, high dispositional mindfulness decreases these risks by 75% or more, and formal mindfulness training has been shown feasible and acceptable. In other high-stress populations formal mindfulness training has improved well-being, stress, cognition and performance, yet the ability of such training to mitigate stress and burnout across medical specialties, or to affect improvements in the cognition and performance of physicians, remains unknown. To address these gaps and thereby promote the wider adoption of contemplative practices within medical training, investigators have developed Enhanced Stress Resilience Training, a modified form of MBSR - streamlined, tailored and contextualized for physicians and trainees. Investigators propose to test Enhanced Stress Resilience Training (ESRT), versus active control and residency-as-usual, in surgical and non-surgical residents evaluated for well-being, cognition and performance changes at baseline, post-intervention and six-month follow-up.


Options:
A: Arm Label: Mental Training for Residents; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Stress Resilience Training (ESRT) | Arm Label: Active Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active Control | Intervention Type: BEHAVIORAL; Name: Enhanced Stress Resilience Training (ESRT); Assigned to Arm(s): Mental Training for Residents | Intervention Type: BEHAVIORAL; Name: Active Control; Assigned to Arm(s): Active Control
B: Arm Label: Mindfulness-based self-care; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness-based self care | Arm Label: Life as usual control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mindfulness-based self care; Assigned to Arm(s): Mindfulness-based self-care
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Corporate Athlete Resilience (CAR) Training Program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Corporate Athlete Resilience (CAR) Training Program; Assigned to Arm(s): Intervention
D: Arm Label: Group therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Manualized Therapy | Arm Label: Control Group; Type: OTHER; Interventions: Behavioral: Control Group | Intervention Type: BEHAVIORAL; Name: Manualized Therapy; Assigned to Arm(s): Group therapy | Intervention Type: BEHAVIORAL; Name: Control Group; Assigned to Arm(s): Control Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Occupational Therapy Interventions Based on Cancer Education on Quality of Life for Colorectal Cancer Survivors
Brief Summary: BACKGROUND:

Colorectal cancer (CRC) and its treatment affect CRC survivors' quality of life (QoL), emotional distress and activities of daily living (ADL). It is assumed that occupational therapy interventions based on cancer education may be a feasible approach.

Aim To examine the effect of using cancer education based on healthy lifestyle by occupational therapist on QoL, emotional distress, ADL and healthy lifestyle behaviors in CRC survivors.

Methods Participants with CRC were designed as a two-group controlled trial, and a single-blind randomized controlled trial was conducted. These participants were randomly assigned to either an OT intervention or a non-intervention group (in a 1:1 ratio). Those participants in the OT intervention group were given a consultation based on a CRC education handbook by an occupational therapist for discharge preparation and on 1-month, 3-month follow-up clinic; the non-intervention group participants were given a CRC education handbook (the same handbook) only for discharge preparation. The primary outcome was the change in QoL measured using WHOOQOL-BREF. Secondary outcomes were changes in emotional distress, ADL and healthy lifestyle behaviors. Outcomes were examined in baseline (discharge preparation), 1-month and 3-months follow-up clinic.


Options:
A: Arm Label: OT intervention group; Type: EXPERIMENTAL; Interventions: Other: Cancer education | Arm Label: non-intervention group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Cancer education; Assigned to Arm(s): OT intervention group
B: Arm Label: Interdisciplinary rehabilitation; Type: EXPERIMENTAL; Interventions: Behavioral: Interdisciplinary rehabilitation | Arm Label: Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Interdisciplinary rehabilitation; Assigned to Arm(s): Interdisciplinary rehabilitation
C: Arm Label: Bone marrow transplantation; Type: OTHER; Interventions: Procedure: Bone marrow transplantation | Arm Label: Peripheral blood stem cell transplantation; Type: OTHER; Interventions: Procedure: Peripheral blood stem cell transplantation | Intervention Type: PROCEDURE; Name: Bone marrow transplantation; Assigned to Arm(s): Bone marrow transplantation | Intervention Type: PROCEDURE; Name: Peripheral blood stem cell transplantation; Assigned to Arm(s): Peripheral blood stem cell transplantation
D: Arm Label: Stepped Care; Type: EXPERIMENTAL; Interventions: Other: Stepped Care | Arm Label: Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Stepped Care; Assigned to Arm(s): Stepped Care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ATHENA (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)
Brief Summary: This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based on homologous recombination (HR) status of tumor samples.


Options:
A: Arm Label: A: Paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Arm Label: B: Olaparib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: C: Olaparib and Cediranib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib, Drug: Cediranib | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): B: Olaparib, C: Olaparib and Cediranib | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): C: Olaparib and Cediranib | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): A: Paclitaxel
B: Arm Label: KU-0059436; Type: EXPERIMENTAL; Interventions: Drug: KU-0059436 (AZD2281)(PARP inhibitor) | Intervention Type: DRUG; Name: KU-0059436 (AZD2281)(PARP inhibitor); Assigned to Arm(s): KU-0059436
C: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: Rucaparib, Drug: Nivolumab | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Rucaparib, Drug: Placebo IV Infusion | Arm Label: Arm C; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Placebo Oral Tablet | Arm Label: Arm D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Oral Tablet, Drug: Placebo IV Infusion | Arm Label: Japanese Open-label Safety Cohort; Type: EXPERIMENTAL; Interventions: Drug: Rucaparib, Drug: Nivolumab | Intervention Type: DRUG; Name: Rucaparib; Assigned to Arm(s): Arm A, Arm B, Japanese Open-label Safety Cohort | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): Arm A, Arm C, Japanese Open-label Safety Cohort | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): Arm C, Arm D | Intervention Type: DRUG; Name: Placebo IV Infusion; Assigned to Arm(s): Arm B, Arm D
D: Arm Label: Niraparib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Active comparator: Niraparib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Active comparator: Niraparib; Assigned to Arm(s): Niraparib | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: BARIVA:Short Versus Extended Prophylaxis of Rivaroxaban for Venous Thromboembolism After Bariatric Surgery
Brief Summary: The aim of this study is to investigate the efficacy and safety of rivaroxaban in obese patients undergoing bariatric surgery.

The objectives are to assess the safety and feasibility of venous thromboembolism (VTE) prophylaxis and lung embolism with Rivaroxaban 10mg as an oral anticoagulant. After bariatric surgery patients receive the study medication Xarelto 10mg QD for 7, resp. 28 days.

All clinically thromboembolic events will be assessed by ultrasound or CT, respectively, as soon as apparent. In addition, patients are screened for VTE at day 28 by ultrasound to detect clinically inapparent thromboses.

In a subgroup of study patients (patients from the University Hospital Inselspital, Bern) PK/PD parameters are assessed following the last intake of rivaroxaban at day 28.


Options:
A: Arm Label: Prophylactic bemiparin (3,500 IU/day); Type: ACTIVE_COMPARATOR; Interventions: Drug: Bemiparin sodium | Arm Label: Full therapeutic bemiparin (weight adjusted); Type: EXPERIMENTAL; Interventions: Drug: Bemiparin sodium | Intervention Type: DRUG; Name: Bemiparin sodium; Assigned to Arm(s): Full therapeutic bemiparin (weight adjusted), Prophylactic bemiparin (3,500 IU/day)
B: Arm Label: A: Rivaroxaban short arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rivaroxaban 10 MG Oral Tablet [Xarelto] | Arm Label: B: Rivaroxaban long arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rivaroxaban 10 MG Oral Tablet [Xarelto] | Intervention Type: DRUG; Name: Rivaroxaban 10 MG Oral Tablet [Xarelto]; Assigned to Arm(s): A: Rivaroxaban short arm, B: Rivaroxaban long arm
C: Arm Label: Nafamostat; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nafamostat Mesilate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Nafamostat Mesilate; Assigned to Arm(s): Nafamostat | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Low-Dose LMWH; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Arm Label: High-Dose LMWH; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): High-Dose LMWH, Low-Dose LMWH

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: BARIVA:Short Versus Extended Prophylaxis of Rivaroxaban for Venous Thromboembolism After Bariatric Surgery
Brief Summary: The aim of this study is to investigate the efficacy and safety of rivaroxaban in obese patients undergoing bariatric surgery.

The objectives are to assess the safety and feasibility of venous thromboembolism (VTE) prophylaxis and lung embolism with Rivaroxaban 10mg as an oral anticoagulant. After bariatric surgery patients receive the study medication Xarelto 10mg QD for 7, resp. 28 days.

All clinically thromboembolic events will be assessed by ultrasound or CT, respectively, as soon as apparent. In addition, patients are screened for VTE at day 28 by ultrasound to detect clinically inapparent thromboses.

In a subgroup of study patients (patients from the University Hospital Inselspital, Bern) PK/PD parameters are assessed following the last intake of rivaroxaban at day 28.


Options:
A: Arm Label: Rosuvastatin; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 40mg Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: 40mg Enoxaparin | Arm Label: 60mg Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: 60mg Enoxaparin | Arm Label: Control; Type: OTHER; Interventions: Other: Control | Intervention Type: DRUG; Name: 40mg Enoxaparin; Assigned to Arm(s): 40mg Enoxaparin | Intervention Type: DRUG; Name: 60mg Enoxaparin; Assigned to Arm(s): 60mg Enoxaparin | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
C: Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: lovastatin; Assigned to Arm(s): N/A
D: Arm Label: A: Rivaroxaban short arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rivaroxaban 10 MG Oral Tablet [Xarelto] | Arm Label: B: Rivaroxaban long arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rivaroxaban 10 MG Oral Tablet [Xarelto] | Intervention Type: DRUG; Name: Rivaroxaban 10 MG Oral Tablet [Xarelto]; Assigned to Arm(s): A: Rivaroxaban short arm, B: Rivaroxaban long arm

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: BARIVA:Short Versus Extended Prophylaxis of Rivaroxaban for Venous Thromboembolism After Bariatric Surgery
Brief Summary: The aim of this study is to investigate the efficacy and safety of rivaroxaban in obese patients undergoing bariatric surgery.

The objectives are to assess the safety and feasibility of venous thromboembolism (VTE) prophylaxis and lung embolism with Rivaroxaban 10mg as an oral anticoagulant. After bariatric surgery patients receive the study medication Xarelto 10mg QD for 7, resp. 28 days.

All clinically thromboembolic events will be assessed by ultrasound or CT, respectively, as soon as apparent. In addition, patients are screened for VTE at day 28 by ultrasound to detect clinically inapparent thromboses.

In a subgroup of study patients (patients from the University Hospital Inselspital, Bern) PK/PD parameters are assessed following the last intake of rivaroxaban at day 28.


Options:
A: Arm Label: A: Rivaroxaban short arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rivaroxaban 10 MG Oral Tablet [Xarelto] | Arm Label: B: Rivaroxaban long arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rivaroxaban 10 MG Oral Tablet [Xarelto] | Intervention Type: DRUG; Name: Rivaroxaban 10 MG Oral Tablet [Xarelto]; Assigned to Arm(s): A: Rivaroxaban short arm, B: Rivaroxaban long arm
B: Arm Label: Full Dose LMWH anticoagulation therapy; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparin | Arm Label: Prophylactic/Intermediate Dose LMWH or UFH therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prophylactic/Intermediate Dose Enoxaparin | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Full Dose LMWH anticoagulation therapy | Intervention Type: DRUG; Name: Prophylactic/Intermediate Dose Enoxaparin; Assigned to Arm(s): Prophylactic/Intermediate Dose LMWH or UFH therapy
C: Arm Label: Rivaroxaban 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rivaroxaban 10 mg | Arm Label: Best locally standardized care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Rivaroxaban 10 mg; Assigned to Arm(s): Rivaroxaban 10 mg
D: Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Arm Label: Fondaparinux; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fondaparinux | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Fondaparinux; Assigned to Arm(s): Fondaparinux

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: BARIVA:Short Versus Extended Prophylaxis of Rivaroxaban for Venous Thromboembolism After Bariatric Surgery
Brief Summary: The aim of this study is to investigate the efficacy and safety of rivaroxaban in obese patients undergoing bariatric surgery.

The objectives are to assess the safety and feasibility of venous thromboembolism (VTE) prophylaxis and lung embolism with Rivaroxaban 10mg as an oral anticoagulant. After bariatric surgery patients receive the study medication Xarelto 10mg QD for 7, resp. 28 days.

All clinically thromboembolic events will be assessed by ultrasound or CT, respectively, as soon as apparent. In addition, patients are screened for VTE at day 28 by ultrasound to detect clinically inapparent thromboses.

In a subgroup of study patients (patients from the University Hospital Inselspital, Bern) PK/PD parameters are assessed following the last intake of rivaroxaban at day 28.


Options:
A: Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard treatment | Arm Label: Bivalirudin arm; Type: EXPERIMENTAL; Interventions: Drug: Bivalirudin Injection | Intervention Type: DRUG; Name: Bivalirudin Injection; Assigned to Arm(s): Bivalirudin arm | Intervention Type: DRUG; Name: Standard treatment; Assigned to Arm(s): Standard treatment
B: Arm Label: A: Rivaroxaban short arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rivaroxaban 10 MG Oral Tablet [Xarelto] | Arm Label: B: Rivaroxaban long arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rivaroxaban 10 MG Oral Tablet [Xarelto] | Intervention Type: DRUG; Name: Rivaroxaban 10 MG Oral Tablet [Xarelto]; Assigned to Arm(s): A: Rivaroxaban short arm, B: Rivaroxaban long arm
C: Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Drug: ASA, Drug: Clopidogrel 75mg | Arm Label: Apixaban group; Type: EXPERIMENTAL; Interventions: Drug: Apixaban, Drug: ASA | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban group | Intervention Type: DRUG; Name: ASA; Assigned to Arm(s): Apixaban group, Control group | Intervention Type: DRUG; Name: Clopidogrel 75mg; Assigned to Arm(s): Control group
D: Intervention Type: DRUG; Name: Rosuvastatin calcium; Assigned to Arm(s): N/A

Answer: B